Head-To-Head Review: Pacific Biosciences of California (PACB) vs. Arrayit (ARYC)

Pacific Biosciences of California (NASDAQ:PACB) and Arrayit (OTCMKTS:ARYC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Earnings & Valuation

This table compares Pacific Biosciences of California and Arrayit’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacific Biosciences of California $93.47 million 10.67 -$92.18 million ($0.87) -8.69
Arrayit N/A N/A N/A N/A N/A

Arrayit has lower revenue, but higher earnings than Pacific Biosciences of California.


This table compares Pacific Biosciences of California and Arrayit’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacific Biosciences of California -100.09% -95.29% -60.07%
Arrayit N/A N/A N/A

Risk and Volatility

Pacific Biosciences of California has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Arrayit has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500.

Institutional & Insider Ownership

70.6% of Pacific Biosciences of California shares are held by institutional investors. 13.4% of Pacific Biosciences of California shares are held by insiders. Comparatively, 58.0% of Arrayit shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Pacific Biosciences of California and Arrayit, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California 0 1 2 0 2.67
Arrayit 0 0 0 0 N/A

Pacific Biosciences of California currently has a consensus target price of $6.10, indicating a potential downside of 19.31%. Given Pacific Biosciences of California’s higher possible upside, equities analysts clearly believe Pacific Biosciences of California is more favorable than Arrayit.


Pacific Biosciences of California beats Arrayit on 5 of the 9 factors compared between the two stocks.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

About Arrayit

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply